Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.60 |
| ▸ | ACHE | P22303 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690490 | 0.78 | NCF1 (0.64) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL29376440 | 0.78 | MYC (0.52) | ACHEALDH1A1HPGDKDM4EGLA | |
| SCHEMBL64767 | 0.78 | MYC (0.52) | ACHEALDH1A1HPGDKDM4EGLA | |
| SCHEMBL323374 | 0.78 | NCF1 (0.64) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL11811408 | 0.77 | MYC (0.50) | ACHEALDH1A1HPGDKDM4EGLA | |
| SCHEMBL11811414 | 0.77 | MYC (0.50) | ACHEALDH1A1HPGDKDM4EGLA | |
| SCHEMBL18493817 | 0.75 | ALDH1A1 (0.50) | NCF1ACHEALDH1A1HPGDKDM4E | |
| SCHEMBL25330955 | 0.75 | NQO2 (0.43) | ACHEALDH1A1HPGDKDM4EGLA | |
| SCHEMBL6535469 | 0.75 | MAOA (0.50) | ACHEALDH1A1HPGDKDM4EGLA | |
| SCHEMBL377555 | 0.75 | CYP1A2 (0.64) | ACHEALDH1A1HPGDKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153865-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | claimed |
| US-7060834-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | claimed |
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | claimed |
| EP-1430030-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | claimed |
| US-20040266819-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | claimed |
| EP-1430030-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | claimed |
| EP-1430029-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003018561-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | claimed |
| WO-2003018560-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | claimed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | disclosed |
| US-7153865-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-7060834-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| EP-1430030-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| US-20040266819-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1430030-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1430029-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003018560-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003018561-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266819-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1G | NCF1 396/4885ACHE 208/4885ALDH1A1 3081/4885 |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | NCF1 3051/4885ACHE 433/4885ALDH1A1 2719/4885 |
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | NCF1 511/4885ACHE 152/4885ALDH1A1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.